Press Releases September 3, 2026 08:00 AM

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Aclaris Therapeutics CEO to Present at 2026 Cantor Global Healthcare Conference

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
ACRS

Aclaris Therapeutics, a clinical-stage biopharmaceutical company focused on immuno-inflammatory disease therapies, announced that its CEO, Dr. Neal Walker, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference. The event will be webcast live and archived for investor access.

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ACRS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Aclaris is advancing novel product candidates for immuno-inflammatory diseases, addressing unmet medical needs.
  • The CEO's participation in a major healthcare conference signals ongoing investor engagement and corporate transparency.
  • Live and archived webcast access provides broad accessibility to the company's strategic discussions.

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday, September 10, 2026, at 2:45 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker will participate in a fireside chat during the 2026 Cantor Global Healthcare Conference in New York, NY.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
[email protected]


Risks

  • As a clinical-stage biopharmaceutical company, Aclaris faces inherent development and regulatory risks related to product candidates.
  • Market acceptance of new therapies for immuno-inflammatory diseases is uncertain and competitive.
  • Conference presentations are informational and may not immediately impact financial performance or product approvals.

More from Press Releases

Final Opportunity to Own a New Luxury Home in Toll Brothers at Tesoro Highlands - Alta Monte Collection in Valencia, California Sep 3, 2026 Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States Sep 3, 2026 CN Reports August Grain Movement Sep 3, 2026 Wellchange Holdings Company Limited Announces 1-for-5 Reverse Stock Split Effective September 8, 2026 Sep 3, 2026 Cosmos Health: A Company Transformed Sep 3, 2026